The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Hypersensitivity reactions (HSRs) can occur with any of the available biologic agents used to treat rheumatoid arthritis (RA). We compared drug‐specific risks for HSRs among RA patients enrolled in the US Medicare program.
Methods
Using Medicare data, we identified new users of infused infliximab, abatacept, rituximab, tocilizumab, golimumab, and injected biologic agents. After identifying...
ObjectiveSelf‐injectable biologic agents have been covered by Medicare Part D since 2006. We hypothesized that this coverage benefit and related financial considerations would lead to increased use of self‐injectable biologic agents over time and would be influential in determining which rheumatoid arthritis (RA) patients received infusion versus self‐injected biologic agents.
MethodsWe used 100%...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.